Genentech’s Giredestrant Nears FDA Decision in Early-Stage Breast Cancer
Event summary
- FDA accepted Genentech’s NDA for giredestrant under Priority Review for ER-positive early-stage breast cancer.
- Phase III lidERA study showed giredestrant reduced invasive disease recurrence or death by 30% vs. standard therapy.
- FDA decision expected by November 30, 2026.
- Giredestrant is the first and only oral SERD with positive Phase III results in the curative setting.
The big picture
Genentech’s giredestrant represents a significant advancement in endocrine therapy for early-stage ER-positive breast cancer, an area with limited innovation for decades. The FDA’s Priority Review designation underscores the unmet need for more effective and better-tolerated treatments. Success could solidify Genentech’s leadership in oncology, particularly in targeting hormone receptor-positive cancers.
What we're watching
- Regulatory Approval
- Whether the FDA will approve giredestrant by the November 30, 2026 deadline, potentially setting a new standard in early-stage breast cancer treatment.
- Clinical Efficacy
- The pace at which giredestrant’s overall survival data matures and whether it confirms the positive trend observed in the lidERA study.
- Market Positioning
- How Genentech positions giredestrant against existing and emerging therapies in the ER-positive breast cancer space.
Related topics